Richard Pilnik speaks with GLG about how healthcare systems in emerging markets can vary and how Type 2 Diabetes treatment is handled differently across various health systems.
Richard recently retired as the EVP and President of Quintiles Global Commercial Solutions (2009 to June 2014) with a focus on the outsourcing needs of the Pharmaceutical Industry covering 65+ Pharma/Biosciences companies located in the USA, Europe, Japan and emerging markets. Quintile is a global company with over 25,000 employees and present in over 50 countries. Prior to this role, Richard retired as Group VP, Chief Marketing Officer at Eli Lilly and Company in June 2008, after a 25 year career working and living in Latin America, Europe, USA and Asia. His experience is based on extensive international assignments in the commercial area of the pharmaceutical business.
His career responsibilities ranged from Sales Representative, Product Manager, Marketing and Sales VP in Venezuela, Brazil and Europe, General Manager Mexico, Regional VP Latin America, President of Europe Middle East Africa and Russia. He has developed and expanded businesses from hyper-inflationary challenged markets to very large multi-country complex enterprises that required integration of the commercial, manufacturing and Clinical/Medical research functions. Richard’s Board experience covers Elan Pharmaceuticals (NUSE: ELN sold to Perrigo in December 2013), Chairman of Diamedica (a Canadian biotech) and Fuqua School of Business at Duke University.